Table 1 Baseline Demographic and Clinical Characteristics of Randomized Participants Classified as Nonremitters During Prior MPH Treatment
Participant | Age (years) | Sex | Weight (kg) | Medication | Total Daily Dose (mg/day) | Average Daily Dose (mg/kg) | Screening ADHD-RS-IV Total Score |
|---|---|---|---|---|---|---|---|
1 | 6 | F | 22.68 | OROS MPH* | ≥ 30 | ≥ 1.0 | 50 |
2 | 7 | M | 29.48 | ER MPH | 20 | < 1.0 | 20 |
3 | 7 | F | 44.45 | OROS MPH | 36 | < 1.0 | 28 |
4 | 8 | M | 44.36 | OROS MPH | 18 | < 1.0 | 38 |
5 | 8 | M | 26.31 | OROS MPH | 54 | ≥ 1.0 | 38 |
6 | 8 | M | 33.57 | OROS MPH; IR dMPH | 54; 2.5 | ≥ 1.0 | 50 |
7 | 8 | M | 41.28 | OROS MPH | 18 | < 1.0 | 43 |
8 | 8 | F | 43.68 | IR MPH | 30 | < 1.0 | 50 |
9 | 9 | M | 29.03 | ER MPH | 20 | < 1.0 | 29 |
10 | 9 | M | 26.76 | OROS MPH | 54 | ≥ 1.0 | 39 |
11 | 9 | M | 31.75 | MPH CD | 40 | ≥ 1.0 | 29 |
12 | 9 | M | 26.31 | OROS MPH | 27 | ≥ 1.0 | 45 |
13 | 9 | F | 28.12 | SR MPH | 20 | < 1.0 | 40 |
14 | 9 | F | 25.18 | IR MPH* | ≥ 50 | ≥ 1.0 | 34 |
15 | 9 | F | 24.90 | OROS MPH | 27 | ≥ 1.0 | 20 |
16 | 10 | M | 39.01 | OROS MPH | 54 | ≥ 1.0 | 23 |
17 | 10 | F | 43.68 | OROS MPH†| 36 | < 1.0 | 22 |
18 | 10 | F | 27.67 | OROS MPH | 54 | ≥ 1.0 | 37 |
19 | 10 | F | 29.03 | IR MPH | 50 | ≥ 1.0 | 44 |
20 | 11 | M | 45.36 | OROS MPH | 72 | ≥ 1.0 | 35 |
21 | 11 | M | 45.36 | OROS MPH | 36 | < 1.0 | 41 |
22 | 12 | M | 39.46 | OROS MPH | 54 | ≥ 1.0 | 45 |
23 | 12 | M | 34.02 | OROS MPH | 18 | < 1.0 | 45 |
24 | 12 | M | 33.57 | OROS MPH | 54 | ≥ 1.0 | 44 |
25 | 12 | F | 34.02 | OROS MPH | 36 | ≥ 1.0 | 51 |
26 | 12 | F | 26.76 | OROS MPH | 54 | ≥ 1.0 | 25 |